Plain-English translation of NCT06537752 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study is watching how breast cancer patients respond to a chemotherapy medication called docetaxel (non-ethanol formulation) when it's given before or after breast cancer surgery. Researchers want to understand what side effects patients experience and whether the medication is safe and well-tolerated. The study will follow over 1,000 patients to gather real-world information about how this treatment works in everyday practice.
Chemotherapy is an important part of treating breast cancer, but doctors need better information about side effects and safety profiles of different formulations to help patients prepare and manage their care. This study aims to fill that gap by carefully documenting patient experiences with this medication in routine clinical practice.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive your planned chemotherapy treatment (which includes the non-ethanol docetaxel formulation) as prescribed by your doctor, either before or after your breast cancer surgery. Throughout your treatment and recovery, you would be monitored and asked to report any side effects or symptoms you experience, and researchers would collect information from your medical records about your response to the medication. The study involves observation and data collection rather than additional procedures — your doctor will track your health and safety as part of your regular cancer care.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
South Korea
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment target
~1,052 participants
Started
July 2024
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shin-young Oh
Boryung Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.